BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III
March 31, 2011
By
Catherine Shaffer
No Comments
Amgen Inc. and Takeda Pharmaceutical Co. Ltd. shared their disappointment today regarding top-line results of a Phase III trial of their VEGF inhibitor, motesanib, for nonsquamous non-small-cell lung cancer (NSCLC).
BioWorld